Survival impact and predictive factors of axillary recurrence after sentinel biopsy

Houvenaeghel, Gilles; Classe, Jean Marc; Garbay, J. R.; Giard, S.; Cohen, Monique; Faure, C.; Charytansky, Hélène; Rouzier, Roman; Daraı̈, Émile; Hudry, Delphine; Azuar, P.; Villet, R.; Gimbergues, Pierre; Lara, C. Tunon de; Martino, Marc; Fraisse, J.; Dravet, F.; Chauvet, Marie Pierre; Gonçalvès, Anthony; Lambaudie, Éric

doi:10.1016/j.ejca.2016.01.019

Cited by 28 publications

(18 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was also a protective factor when assessing the overall risk for isolated axillary recurrence, indicating that the false-negative rate decreases with a higher number of SNs removed 18 . Tumour size was found to be predictive of breast cancer death but not of axillary recurrence, which is in line with recent findings by Houvenaeghel and colleagues 19 .…”

Section: Discussionsupporting

confidence: 91%

Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study

Boniface

Frisell

Bergkvist

et al. 2017

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study

Boniface

Frisell

Bergkvist

et al. 2017

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…19 Houvenaeghel et al . 22 reported that 14,095 patients who underwent surgery for clinically N0 previously untreated breast cancer and who had sentinel node biopsy experienced a 0.51 percent axillary recurrence rate with a median time to onset of 43 months.…”

Section: Discussionmentioning

confidence: 99%

Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases

et al. 2016

View full text Add to dashboard Cite

Background and Objective The early results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in locoregional recurrence for patients with positive sentinel lymph nodes (SLN) randomized either to axillary lymph node dissection (ALND) or SLN dissection (SLND) alone. We now report long-term locoregional recurrence results. Methods ACOSOG Z0011 prospectively examined overall survival of patients with SLN metastases undergoing breast-conserving therapy randomized to undergo ALND after SLND or no further axillary specific treatment. Locoregional recurrence was prospectively evaluated and compared between the groups. Results Four hundred forty-six patients were randomized to SLND alone and 445 to SLND plus ALND. Both groups were similar with respect to age, Bloom-Richardson score, ER status, adjuvant systemic therapy, histology, and tumor size. Patients randomized to ALND had a median of 17 axillary nodes removed compared to a median of only 2 SLNs removed with SLND alone (P < 0.001). ALND, as expected, also removed more positive lymph nodes (P < 0.001). At a median follow-up of 9.25 years, there was no statistically significant difference in local recurrence-free survival (P=0.13). The cumulative incidence of nodal recurrences at 10 years was 0.5% in the ALND arm and 1.5% in the SLND alone arm (P=0.28). Ten-year cumulative locoregional recurrence was 6.2% with ALND and 5.3% with SLND alone (P=0.36). Conclusion Despite the potential for residual axillary disease after SLND, SLND without ALND offers excellent regional control for selected patients with early metastatic breast cancer treated with breast-conserving therapy and adjuvant systemic therapy.

show abstract

“…The French population cohort included all patients treated for early BC with cN0 and SLNB in any of the 15 cancer centers in France between March 1999 and March 2012 [ 24 ]. Out of the 23,000 patients treated for breast cancer included in the French cohort, we included all 1863 patients who had SN micro-metastases in this study (an average of 143 patients per year).…”

Section: Methodsmentioning

confidence: 99%

External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis

Houvenaeghel

Hajj

Barrou

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Many trials confirmed the safety of omitting axillary dissection in the selected patients treated for early breast cancer. The external validity of these trials is questionable. Our study aimed to evaluate the accuracy of the French population representativity in the SERC trial and the differences between these two populations as well as comparing the French and the Swedish populations (the SENOMIC trial population and the Swedish National Breast Cancer Registry (NKBC) cohort) of patients with sentinel node (SN) micro-metastasis. A higher rate of smaller tumors and grade 1 tumors was observed in the French cohort when compared to the SERC population. Our findings conclude that both French populations show similar characteristics. Positive non-sentinel node (NSN) rates at completion axillary lymph node dissection (ALND) were 10.28 % and 11.3 % in the SERC trial and French cohort, respectively (p = 0.5). The rate of grade 1 tumors was lower in the SENOMIC trial (16.2%) and in the NKBC cohort (17.4%) compared to the SERC trial population (27.3%) and the French cohort (34.4%). Our findings in addition to the previously demonstrated concordance between the SENOMIC trial and the NKBC populations imply that the results of both the SERC and the SENOMIC trials can be applied to both French and Swedish real populations.

show abstract

Survival impact and predictive factors of axillary recurrence after sentinel biopsy

Cited by 28 publications

References 40 publications

Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study

Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study

Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases

External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis

Contact Info

Product

Resources

About